



213 Sterling Road, Suite 206  
Toronto, ON M6R 2B2  
Canada  
Ph: (416) 262-0871  
Email: [ir@sirebioscience.com](mailto:ir@sirebioscience.com)  
[www.sirebioscience.com](http://www.sirebioscience.com)

## Sire Bioscience Announces Further Update on March 31, 2020 Q2 Interim Filing

**Toronto, Ontario, June 29, 2020 – Sire Bioscience Inc. (“SIRE”) (CSE:SIRE) (OTC:BLLXF) (FSE:BR1B) (“Sire” or the “Company”)** announces that, further to its news release of May 29, 2020, the Company is continuing to work diligently to file its interim financial statements for the second quarter ended March 31, 2020 by July 16, 2020 pursuant to BC Instrument 51-515 *Temporary Exemption from Certain Corporate Finance Requirements* (“**BCI 51-515**”).

The Company will be relying on the temporary exemption pursuant to BCI 51-515 in respect to the following provisions:

- the requirement to file interim financial statements for the six months ended March 31, 2020 (the “**Financial Statements**”) within 60 days after the end of the Company's interim period as required by section 4.4(b) of National Instrument 51-102 *Continuous Disclosure* (“**NI 51-102**”);
- the requirement to file management discussion and analysis (the “**MD&A**”) for the period covered by the Financial Statements within 60 days after the end of the Company's interim period as required by section 5.1(2) of NI 51-102; and
- the requirement to file certifications of the Financial Statements (the “**Certificates**” and together with the Financial Statements, the “**Interim Filings**”) pursuant to section 5.1 of National Instrument 52-109 *Certification of Disclosure in Issuer’s Annual and Interim Filings* and section 4.4(b) [being the filing deadline for interim financial statements] of NI 51-102.

The Company confirms that there have been no material developments, other than those disclosed through news releases and Form 7 *Monthly Progress Reports* filed on the Company’s profile with the Canadian Securities Exchange, since the filing of its condensed interim consolidated financial statements for the three months ended December 31, 2019.

Additionally, the Company advises that management and other insiders of the Company are subject to a trading black-out policy as described, in principle, in section 9 of National Policy 11-207, Failure to-File Cease Trade Orders and Revocations in Multiple Jurisdictions.

### About Sire Bioscience

SIRE’s principal business activity is to engage in the investment, production of, and sale of hemp. Its mission is to execute on brand offerings that connect with people and build top of mind awareness.

SIRE is headquartered in Mississauga, Ontario and is backed by a group of successful entrepreneurs who have extensive experience in the areas of manufacturing, consumer packaged goods, logistics, and distribution. It has secured a state-of-the-art agricultural facility in Leamington, Ontario – a preeminent locale for hemp cultivation in Canada.

### FOR INFORMATION, CONTACT:

#### Sire Bioscience Inc.

E: [ir@sirebioscience.com](mailto:ir@sirebioscience.com)

*The CSE and Information Service Provider have not reviewed and does not accept responsibility for the accuracy or adequacy of this release.*